New biologic AZD7798 tested in early Crohn's trial

NCT ID NCT05452304

Completed Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study tested a new biologic drug called AZD7798 in 112 people, including healthy volunteers and patients with Crohn's disease. The main goal was to check if the drug is safe and how the body processes it. Researchers gave single or repeated doses and monitored for side effects. This is a first step to see if AZD7798 might be a future treatment for Crohn's.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: AZD7798 (a biologic drug given by injection or infusion)
What this could lead to: If successful, this could lead to a new treatment option for Crohn's disease, helping to control inflammation and symptoms.
What could go wrong: This is a very early Phase 1 trial focused on safety, not effectiveness. The drug may not work or could have side effects. Results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CROHNS DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Crohn disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CROHNS DISEASE HEALTHY SUBJECTS

Contacts and locations

Locations

Research Site

Harrow, HA1 3UJ, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.